Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management. Neurofilaments, which are markers of neuronal lysis, appear to be a promising biomarker. In a previous preliminary study, the investigators demonstrated significantly lower concentrations of neurofilaments in CSF of psychiatric patients compared to neurodegenerative diseases.
The main objective of this study is to validate the plasma assay of neurofilament light chain as a biomarker for the differential diagnosis of psychiatric or neurodegenerative cognitive impairment. Other biomarkers of interest (Tau, TDP-43, GFAP and UCH-L1) will also be analyzed.
A sub-part of this study will also focus on the retrospective analysis of the CSF/Plasma correlations of the different biomarkers mentioned above from tube bottom samples taken in routine care.
One hundred twenty participants will be included in this study
All the participants will perform cognitive, behavioral, and psychiatric evaluation and will be have blood sample taken.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participant with psychiatric condition without cognitive impairment | Experimental | In the psychiatric condition group without cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria. |
|
| Participant with psychiatric condition with cognitive impairment | Experimental | In the psychiatric condition group with cognitive impairment will be included participants with schizophrenia or bipolar disorder according to DSM V criteria. To date, there are no clinical criteria for defining the dementia evolution of psychiatric disorders. The diagnosis of psychiatric disorder with cognitive involution is often made on the basis of subjective criteria or on the appreciation of health care teams. In the present study, cognitive involution will be defined by the occurrence of cognitive deterioration objectified by disturbed neuropsychological tests and the occurrence of progressive behavioral changes contrasting with the person's previous state and reported by the care team, a member of the family or by the patient himself. Cognitive involution must be accompanied by a decrease in autonomy with respect to the person's previous abilities. |
|
| Patients with biological Alzheimer's disease | Experimental | Alzheimer's disease with frontal, amnestic, language, and visual presentation with typical Alzheimer CSF according to the 2011 NIA-AA diagnostic criteria. |
|
| Patient with fronto-temporal dementia | Experimental |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| blood sample taken | Diagnostic Test | Comparaison of Neurofilament light chain serum concentration between the arms |
|
| Measure | Description | Time Frame |
|---|---|---|
| neurofilament light chain | serum neurofilament light chain concentration | two months |
| Measure | Description | Time Frame |
|---|---|---|
| Total tau | serum tau protein concentration | two months |
| GFAP Glial fibrillary acidic protein | Serum GFAP concentration | two months |
Not provided
Inclusion Criteria:
Participants with psychiatric conditions:
Participants with neurodegenerative disease:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dorey Jean-Michel, MD,PHD | Contact | 0437915249 | +33 | jean-michel.dorey@ch-le-vinatier.fr |
| SARTELET lydie | Contact | 0437915531 | +33 | lydie.sartelet@ch-le-vinatier.fr |
| Name | Affiliation | Role |
|---|---|---|
| Jean-Michel DOREY, MD, PHD | CH le Vinatier | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| HCL Consultation mémoire Neurologique -Hôpital Neurologique | Recruiting | Bron | 69677 | France |
Clinical and biological IPD
4 years
all criterias
Not provided
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D001714 | Bipolar Disorder |
| D000544 | Alzheimer Disease |
| D003704 | Dementia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
| D000068105 | Bipolar and Related Disorders |
| D019964 | Mood Disorders |
Not provided
Not provided
Four groups of participants will be recruited: participant with psychiatric condition without cognitive impairment, participants with psychiatric condition with cognitive impairment, participants with biological Alzheimer's disease, and participant with fronto-temporal dementia
Not provided
Not provided
Not provided
Not provided
Probable or definite Fronto-temporal dementia, mostly behavioral variant of FTD (according to the diagnostic criteria for FTDb of Rascovsky, 2011) but Semantic Disease, Primary Progressive Non-Fluent Aphasia, Progressive Supra-Nuclear Palsy-DFT will be accepted if behavioral onset. |
|
|
| neurofilament heavy chain (pNF-h) | Serum neurofilament heavy chain (pNF-h) concentration | two months |
| Centre Hospitalier Le Vinatier | Recruiting | Bron | 69678 | France |
|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |